CerTest Biotec, BD announced addition of saliva to CE Marked VIASURE SARS-CoV-2 Real Time PCR Detection Kit for BD MAX
On Apr. 27, 2021, CerTest Biotec, along with BD announced the VIASURE SARS-CoV-2 (N1 + N2) Real Time…
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Moderna announced that it had entered into an agreement with Sanofi for fill/finish sterile…
NIH established new childhood asthma clinical research network
On Apr. 23, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had awarded…
COVID-19 infections survey revealed significant reductions in COVID-19 infections with single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
On Apr. 23, 2021, University of Oxford data from the COVID-19 Infection Survey was the first to show…
INOVIO planned for ex-US global phase 3 trial for INO-4800
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
Large NIH clinical trial tested polyclonal antibody therapeutic for COVID-19
On Apr. 21, 2021, the NIH announced that a Phase 2/3 trial to evaluate a new fully-human polyclonal…
Moderna announced new COVID-19 vaccine supply agreement with Israel for 2022
On Apr. 20, 2021, Moderna announced a new supply agreement with Israel for 2022 whereby Israel also retained…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Therapeutics | Vaccine
Broad Institute expanded COVID-19 viral sequencing efforts for variant surveillance in the Northeast
On Apr. 19, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
Mayo Clinic study found colon cancer driven by hereditary gene mutations in 1 in 6 patients
On Apr. 19, 2021, the Mayo Clinic announced a study that bolstered evidence that colorectal cancer is often…
Texas A&M lab identified new COVID-19 variant; genome suggested potential resistance to antibodies
On Apr. 19, 2021, scientists at the Texas A&M University Global Health Research Complex (GHRC) announced they had…
CytoDyn submitted Most Crucial Section of interim order to Health Canada for COVID-19 under rolling review
On Apr. 19, 2021, CytoDyn announced it had submitted the manufacturing section (CMC) of the application for an…
researchers discovered a gene that causes the most common form of muscular dystrophy in adults
On Apr. 15. 2021, a team of researchers led by the University of Minnesota Medical School announced they…
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
Global shortage of innovative antibiotics fueled emergence and spread of drug-resistance
On Apr. 15, 2021, the World Health Organization (WHO) reported that the world was still failing to develop…
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
CytoDyn executed agreement with Chiral Pharma to provide up to 200,000 vials of leronlimab to Philippines
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
Moderna announced clinical progress from mRNA Vaccine
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Company’s COVID-19 variant-specific vaccine…
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
Biotechnology | Diagnostics | Disease | Life Science News | Medical Device | Medicine | Therapeutics
Mayo Clinic launched new technology platform ventures to revolutionize diagnostic medicine
On Apr. 14, 2021, the Mayo Clinic announced a new technology platform initiative to deliver the next generation…
Moderna updated clinical and supply on COVID-19 vaccine program
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Company’s COVID-19 variant-specific…
Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
The Priestley Medal was awarded to Paul Alivisatos
On Apr. 9, 2021, the American Chemical Society awarded The Priestley Medal to Paul Alivisatos “to recognize distinguished…
Biotechnology | COVID-19 | Life Science News | NIH | Therapeutics | Vaccine
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…